Beyond the Needle

Radiomics converts standard CT, MRI and PET scans into high-dimensional, mineable data, extracting quantitative features on tumor texture, shape, and intensity that are invisible to the naked eye. It functions as a “virtual biopsy,” allowing clinicians to infer tumor biology, genomic status, and likely treatment response directly from imaging already collected for staging or surveillance. This matters because it reduces reliance on invasive tissue sampling, which is risky, costly, and typically captures less than 0.1% of a tumor's total volume. To understand the full clinical and economic case, our guide offers an in-depth perspective that may support your decision-making process.

A conventional needle biopsy is a single-point sample that captures only a tiny fraction of a heterogeneous tumor and carries real procedural risk, such as bleeding, infection, or pneumothorax. Radiomics instead analyzes the tumor's entire visible volume in three dimensions using imaging that is already part of routine care, capturing global heterogeneity without added risk or cost.

Radiomics does not replace tissue diagnosis outright, but it complements it by tracking how a tumor evolves over time in a way a static sample cannot.

Radiomics is actively applied to non-invasive genomic profiling (radiogenomics) to infer mutation status such as EGFR in lung cancer, as well as treatment-response prediction and risk stratification in glioblastoma, melanoma immunotherapy, spinal metastasis, and immune monitoring. Beyond oncology, applications are extending into neurology, cardiology, liver disease, and pharmaceutical research, supporting diagnosis, prognosis, and drug development.

Three practical hurdles remain: reproducibility (feature values are highly sensitive to scanner hardware and imaging protocols), statistical rigor (early studies were prone to overfitting on small patient cohorts), and clinical trust in “black box” AI predictions. Standards bodies such as the Image Biomarkers Standardization Initiative (IBSI) and frameworks like the CLAIM checklist are addressing these gaps, while explainable AI tools help clinicians understand model reasoning before acting on it.

The field is moving from single, static scans toward multimodal and longitudinal analysis, combining radiomic signatures with liquid biopsy data, electronic health records, and tissue genomics into unified predictive models. Longitudinal radiomics can flag treatment response weeks before a tumor shrinks enough to meet traditional evaluation criteria.

Implementation follows a structured pipeline: image acquisition and harmonization, preprocessing, tumor segmentation, feature extraction (using tools like PyRadiomics), and feature selection and model building. Organizations should start by auditing existing imaging workflows and data quality, since feature values are highly sensitive to scanner and protocol variation.

Consult with healthcare and medical imaging solution experts to successfully integrate this pipeline into your clinical workflow.

Because feature computation is sensitive to scanner hardware, slice thickness, and reconstruction algorithms, organizations require harmonized imaging protocols, standardized segmentation practices, and validation on independent external cohorts before clinical use. Governance should also address model explainability and align with standards such as IBSI and the CLAIM checklist to ensure findings are reproducible rather than artifacts of technical noise. Consult with healthcare data infrastructure and governance solution experts to ensure your radiomics adoption is built on harmonized imaging protocols, standardized segmentation, and rigorous compliance with IBSI and CLAIM standards.

A credible radiomics model must be trained and then tested on an independent cohort it has never seen, using feature-selection techniques such as Lasso regression to avoid overfitting when the number of extracted features vastly exceeds the patient sample size. Explainable AI techniques, including attention maps, are increasingly used to confirm that a model's predictions align with known tumor pathology, which builds the clinical confidence required for bedside adoption.

Radiomics is designed to extract additional value from scans already acquired for staging or surveillance, rather than requiring new imaging studies. In practice, this means integrating segmentation and feature-extraction tools alongside existing radiology workflows, and eventually linking outputs with EHR and genomic data for unified, multimodal predictive models.

Consult with healthcare imaging and workflow solution experts to learn how radiomics can seamlessly integrate into your existing clinical environment.

Moving from academic pilots to routine practice requires standardized data pipelines, cross-site protocol harmonization, model validation on external data, and change management to build clinician trust in AI-driven outputs. Given the technical and regulatory complexity involved, engaging experienced healthcare technology and data governance specialists can help de-risk the transition.

Consult with healthcare technology solution experts effectively bridge this gap and scale your clinical AI initiatives safely.

Radiomics reduces reliance on repeated invasive procedures, lowers costs tied to pathology processing and molecular sequencing, and enables continuous, non-invasive monitoring of how a tumor evolves under treatment. It also accelerates decision-making, for example, by generating a genomic likelihood score from an existing scan while formal tissue sequencing is still underway.

A single needle biopsy carries thousands of dollars in pathology and sequencing costs plus procedural risk, and can rarely be repeated to track a tumor's evolution. Radiomics draws additional clinical value from imaging that has already been acquired for staging or surveillance, at minimal incremental cost, while also reducing unnecessary follow-up procedures, such as surgeries triggered by ambiguous lung nodule findings

Returns come from several directions:

• Fewer invasive procedures and their associated complication costs
• Earlier identification of non-responders to therapy, avoiding costly, ineffective treatment cycles
• Reduced unnecessary follow-up interventions.
• Faster time-to-decision, reducing length of stay for inpatient oncology populations

Consult with healthcare AI and radiomics solution experts to calculate the specific financial impact for your institution.

Beyond oncology, radiomics is being adopted in neurology, cardiology, liver disease, and pharmaceutical research to support more accurate diagnosis, risk stratification, and drug development. Commercial AI-driven imaging biomarker platforms are already helping pharmaceutical companies and clinical research organizations enhance trial design and personalize patient care, positioning early adopters ahead in precision medicine capabilities. These insights are designed to support high-level decision-making; for in-depth expertise, consulting with experienced subject matter experts is beneficial.

• Demonstrated external validation (not just single-cohort accuracy claims)
• Alignment with standardization frameworks like IBSI
• Explainable AI capabilities that clinicians can trust
• Proven deployment across leading oncology centers and hospitals
• Support for multimodal integration with genomic and EHR data

Take the Next Step
Evaluating these platforms requires balancing deep technical standards with real-world clinical goals. Consult with healthcare solution experts to learn how to seamlessly integrate a validated, compliant radiomics platform into your organization's workflow.